Clinical Trials Browser

INDUSTRY × lenvatinib × 30 days × Clear all

NCT05775159 2026-04-17

Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer

Phase 2 Recruiting

294 enrolled

Gastrointestinal

Biliary Tract Neoplasms, Carcinoma, Hepatocellular

NCT07405164 2026-04-17

MK-6482-043

Phase 3 Recruiting

450 enrolled

Genitourinary

Carcinoma, Renal Cell, von Hippel-Lindau Disease

NCT04164199 2026-04-14

Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

Phase 3 Active not recruiting

404 enrolled

Advanced Malignancies

NCT03486873 2026-04-13

MK-3475-587

Phase 3 Recruiting

3,500 enrolled

Other hematologic neoplasm

Hematologic Neoplasms

NCT04938817 2026-04-13

KEYNOTE-B98

Phase 1/2 Recruiting

110 enrolled

Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Small Cell Lung Carcinoma

NCT04305054 2026-04-08

KEYMAKER-U02

Phase 1/2 Active not recruiting

315 enrolled

Dermatologic

Diabetes Mellitus, Insulin-Dependent, 12, Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT05301842 2026-04-07

EMERALD-3

Phase 3 Active not recruiting

760 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT04039607 2026-04-06

CheckMate 9DW

Phase 3 Active not recruiting

732 enrolled 3 FDA

Gastrointestinal

Carcinoma, Hepatocellular

NCT04199104 2026-03-27

A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010)

Phase 3 Completed

511 enrolled 20 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT05024214 2026-03-25

Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors

Phase 1/2 Recruiting

170 enrolled

GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular

NCT06858813 2026-03-25

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)

Phase 1 Recruiting

232 enrolled

Gastrointestinal

Liver Neoplasms

NCT04008797 2026-03-24

A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor

Phase 1/2 Active not recruiting

301 enrolled

GastrointestinalGynecologic

Carcinoma, Hepatocellular, Liver Neoplasms, Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT05319730 2026-03-20

MK-3475-06B

Phase 1/2 Recruiting

230 enrolled

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT03517449 2026-03-19

MK-3475-775

Phase 3 Completed

827 enrolled 34 charts 2 FDA

Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Endometrial Neoplasms

NCT06036836 2026-03-19

MK-4280A-010

Phase 2 Completed

163 enrolled

Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Endometrial Neoplasms